No Data
No Data
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
How Is The Market Feeling About Krystal Biotech?
Krystal Biotech's (NYSE:KRYS) short percent of float has risen 5.73% since its last report. The company recently reported that it has 2.59 million shares sold short, which is 12.0% of all regular shar
Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing
Julian S Gangolli, Director, on May 20, 2024, sold 20,000 shares in Krystal Biotech (KRYS) for $3,282,690. SEC Filing: https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/xslF345X03/wk-
Krystal Biotech(KRYS.US) Director Sells US$3.28 Million in Common Stock
$Krystal Biotech(KRYS.US)$ Director Gangolli Julian S sold 20,000 shares of common stock on May 20, 2024 at an average price of $164.1345 for a total value of $3.28 million.Source: Announcement What i
No Data